KBTBD13 is a novel cardiomyopathy gene

Josine M. de Winter, Karlijn Bouman, Joshua Strom, Mei Methawasin, Jan D. H. Jongbloed, Wilma van der Roest, Jan van Wijngaarden, Janneke Timmermans, Robin Nijveldt, Frederik van den Heuvel, Erik-Jan Kamsteeg, Baziel G. van Engelen, Ricardo Galli, Sylvia J. P. Bogaards, Reinier A. Boon, Robbert J. van der Pijl, Henk Granzier, Bobby Koeleman, Ahmad S. Amin, Jolanda van der VeldenJ. Peter van Tintelen, Maarten P. van den Berg, Karin Y. van Spaendonck-Zwarts, Nicol C. Voermans, Coen A. C. Ottenheijm

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

KBTBD13 variants cause nemaline myopathy type 6 (NEM6). The majority of NEM6 patients harbors the Dutch founder variant, c.1222C>T, p.Arg408Cys (KBTBD13 p.R408C). Although KBTBD13 is expressed in cardiac muscle, cardiac involvement in NEM6 is unknown. Here, we constructed pedigrees of three families with the KBTBD13 p.R408C variant. In 65 evaluated patients, 12% presented with left ventricle dilatation, 29% with left ventricular ejection fraction< 50%, 8% with atrial fibrillation, 9% with ventricular tachycardia, and 20% with repolarization abnormalities. Five patients received an implantable cardioverter defibrillator, three cases of sudden cardiac death were reported. Linkage analysis confirmed cosegregation of the KBTBD13 p.R408C variant with the cardiac phenotype. Mouse studies revealed that (1) mice harboring the Kbtbd13 p.R408C variant display mild diastolic dysfunction; (2) Kbtbd13-deficient mice have systolic dysfunction. Hence, (1) KBTBD13 is associated with cardiac dysfunction and cardiomyopathy; (2) KBTBD13 should be added to the cardiomyopathy gene panel; (3) NEM6 patients should be referred to the cardiologist.

Original languageEnglish
Pages (from-to)1860-1865
Number of pages6
JournalHuman mutation
Volume43
Issue number12
Early online date2022
DOIs
Publication statusPublished - 6 Nov 2022

Keywords

  • KBTBD13
  • NEM6
  • cardiomyopathy
  • congenital myopathy

Cite this